(Note: cette page n'existe qu'en anglais - Nota: deze pagina bestaat enkel in het Engels)

 

The 8th Meeting of the European Advisory Committees on Biosafety in the field of contained use and deliberate release of GMOs (MEACB 2017) was held on 23 and 24 November 2017 in Liège, Belgium.

Programme

Click here for the programme of the conference.

Presentations

Please find hereunder the PDF-versions of the MEACB 2017 presentations for which the speakers agreed to their publication.

• SESSION I: Evidence-based risk management
  • The conduct of a vaccine study with a novel live attenuated polio vaccine, under containment (Hilde Revets)
  • Evidence-based biosafety (Nicolas Willemarck)
  • Environmental risk assessment of GMO medicinal products - New procedures, new challenges? (Swantje Strassheim)
• SESSION II: High-throughput technologies for molecular characterization and risk assessment of GMOs
  • How mutagenic is Agrobacterium tumefaciens-mediated transformation? Whole genome sequencing of transgenic plants (Henk Schouten)
  • How to assess the safety of new plant varieties in the years to come? (Esther Kok)
• SESSION III: Novel developments in GM plants
  • RNAi-based GM crops: Biosafety and risk assessment considerations (Olivier Christiaens)
• ROUND-TABLE DISCUSSION: Challenges for risk assessment and regulation of GMO's
  • Presentation by Katia Pauwels
  • Presentation by Cécile van der Vlugt
• SESSION IV: GMO medicinal products for human or veterinary use
  • Plasmid vaccines: considerations on the integration potential into the genome and on the risk assessment of non-heritable traits (Matthew Ramon)
  • Risk considerations of the growing biomedical use of herpesvirus vectors (Filip Lim)
• SESSION V: Increasing dissemination and use of scientific contributions on GM risk assessment
  • CADIMA: An open-access online tool and database increasing the transparency and traceability of (GMO) impact data (Christian Kohl)
  • Explanatory note on literature searching conducted in the context of GMO applications (Irene Muñoz Guajardo)
• SESSION VI: Biosafety by design
  • Risk Assessment and Management of Gene Drive Technology (Cécile van der Vlugt)
  • Biosafety: what Xenobiology has to offer (Marleen Renders)
• KEYNOTE LECTURE: Environmental risk assessment of a potential release of GM mosquitoes on the island of Saba (Boet Glandorf)